In advanced PCa, many therapeutic strategies have targeted the lipogenic phenotype of PCa such as inhibitors of de novo FA synthesis (i.e., FASN, ATP citrate lyase, acetyl-CoA carboxylase), FA elongation (i.e., elongase of very-long fatty acid 5), FA desaturation (i.e., stearoyl-CoA desaturase 1), and FA oxidation (i.e., carnitine palmitoyltransferase 1) reviewed in [23]. Here, ACLY is linked to posterior cortical atrophy.